Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA To view or add a comment, sign in Key Updates in NICE 2026 Guidelines for Type 2 Diabetes The NICE 2026 guideline update (NG28) introduces an important shift in the initial drug management of Type 2 Diabetes, emphasizing early cardiometabolic protection and individualized therapy based on comorbidities
Gently massage onto the face or body in circular motions

Key Takeaways GLP-1 medications aren't causing gestational diabetes they may have been masking underlying metabolic dysfunction that becomes visible when the medication is stopped Thyroid problems can be "unmasked" by GLP-1 treatment because the medications signal to your brain that you're not starving, allowing the pituitary TSH to rise, sometime uncovering a pre-existing thyroid issue Zepbound may improve iron absorption if iron levels go too high, testing for hemochromatosis may be warranted To reduce injection site reactions: warm the medication to room temperature, clean and prep skin but don't over-rub with alcohol, inject at exactly 90 degrees, don't pinch the skin, and stay relaxed Diets cause fat regain at the cellular level it's chemistry, not willpower and the fat often accumulates in the visceral area around organs There's no need to increase your GLP-1 dose if you're making good progress an annual weight loss rate of 15% or higher is considered strong Notable Quote "You can't think that just because somebody's weight is high, it's because something they're doing is wrong

This suggests GLP-1 drugs may act earlier in the addiction cycle, reducing cue reactivity and craving, rather than reducing reward after use
The little things can really help your mental health